Irvine Pharmaceutical Services, Inc. will open a new analytical facility in Hangzhou, China. The new 115,000-sq.-ft. facility will expand Irvine’s service offerings into the Asian market and is scheduled to be fully operational in 1Q15.
 
Chief executive officer and founder, Dr. Assad J. Kazeminy said, ” Irvine is responding to the rising needs of large multi-national pharmaceutical companies that are looking for contract organizations overseas that include robust cGMP quality infrastructure and technical expertise. Irvine will now have a local presence and a strong understanding of the local market to offer the region high quality analytical support.”
 
Irvine provides cGMP contract development and manufacturing services including parenteral manufacturing (liquid and lyophilized), preformulation/formulation development, analytical development, biopharmaceutical development, stability storage, analytical chemistry, structural chemistry, microbiology, and drug delivery device testing.